No Data
No Data
Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Subject for Tumor Drug Trial
Selected Announcements: Meitu expects adjusted net income to increase by over 80% in the first half of the year; China Cinda expects net income to decline 40%-50% in the first half of the year.
China Railway has won multiple projects with a total investment of over 43 billion yuan; Peijia Medical-B: revenue in the first half of the year increased by 28.9%-37.8% year-on-year.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced completion of enrollment of the first participant in Phase I clinical trial of injectable FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.
Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) has announced that the Phase I clinical study of the injection FZ-AD005 antibody conjugate (i.e., anti-DLL3 antibody conjugate BB05) developed by the company for the treatment of late-stage solid tumors has successfully enrolled its first subject.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) completed the first subject enrollment for its cancer treatment drug.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that its subsidiary's injection FZ-AD005 monoclonal antibody conjugate for treating advanced solid tumors completed the first subject enrollment in Phase I clinical trial. It is reported that the drug is intended to be used for the treatment of advanced solid tumors, including but not limited to small cell lung cancer, large cell neuroendocrine carcinoma, prostate cancer, etc. Fudan-Zhangjiang received the clinical trial application acceptance notice for the drug in October 2023 and received the clinical trial approval in December 2023. The Phase I clinical trial of the drug aims to evaluate its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors.
Fudan, Zhangjiang (688505.SH): Not involved in stem cell transplant-related technology
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. stated on the interactive platform on July 23 that the group mainly engages in innovative research and development, production and marketing of biomedical products, and has not been involved in the technology of stem cell transplantation.
Express News | The State Council has approved the "Implementation Plan for Supporting the Development of Innovative Drugs across the Whole Value Chain".
No Data